Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

DenmarkBack to Denmark

Clinical trials in Herlev – page 101

1 426 clinical trials in Herlev, Denmark across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

DenmarkOur site in DenmarkKliniske-Forsoeg.dk(opens in a new tab)
Herlev at a glance
1 426
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 426 trials in Herlev

Open in trial search

Eosinophilic granulomatosis with polyangiitis

Not recruiting

Study on the Effectiveness and Safety of Depemokimab vs. Mepolizumab for Adults with Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Cardiac failure

Not recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Neoplasm malignant+2

Not recruiting

Study on the Effects of Selpercatinib in Children with Advanced RET-Altered Solid Tumors or Primary Central Nervous System Tumors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Selpercatinib
  • Sponsor:Loxo Oncology Inc.

Pulmonary arterial hypertension

Not recruiting

Study on Long-term Safety of Seralutinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Pulmonary hypertension

Not recruiting

Study on the Long-term Safety and Efficacy of Ralinepag for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Type 1 diabetes mellitus

Not recruiting

Study on the Safety and Feasibility of Diamyd (Glutamate Decarboxylase 2) for Individuals Aged 8-17 at Risk for Type 1 Diabetes with HLA DR3-DQ2 Haplotype

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Sponsor:Diamyd Medical AB

Neoplasm malignant

Not recruiting

Study on the Safety and Anti-tumor Effects of GEN1042 Alone or with Pembrolizumab and Chemotherapy in Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Genmab A/S

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Fabry's disease

Not recruiting

Study of venglustat tablets to reduce neuropathic and abdominal pain in patients aged 16 and older with Fabry disease who are untreated or haven't received treatment for 6 months

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Venglustat
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Primary amyloidosis

Not recruiting

Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Other cities in Denmark

The busiest research cities in the country

All 45 cities in Denmark

Clinical research in Herlev

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, particularly in endometrial, prostate, and bladder cancers. Studies are evaluating novel combination therapies and immunological approaches.

  • Endometrial Cancer Treatment Studies
  • Metastatic Prostate Cancer Therapies
  • Bladder Cancer Interventions

Research aims to improve treatment outcomes and survival rates through targeted therapeutic approaches.

02 Cardiovascular and Metabolic Studies

Comprehensive research into heart failure prevention and treatment of metabolic conditions, including studies on innovative drug combinations and biomarker-targeted approaches.

  • Heart Failure Prevention Trials
  • Diabetes and Kidney Disease Research
  • Obesity Management Studies

Focus on developing preventive strategies and improving patient outcomes in cardiovascular conditions.

03 Preventive Medicine

Studies examining vaccine effectiveness and preventive treatments, particularly in meningococcal and varicella infections. Research includes both pediatric and adult populations.

  • Meningococcal Vaccine Studies
  • Chickenpox Vaccination Research
  • Immunization Response Analysis

Emphasis on developing safe and effective preventive measures for infectious diseases.

Back to DenmarkAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.